Objective:

To evaluate longitudinal changes in breast function and health-related quality of life following surgical treatment for plasma cell mastitis.

Approach:

Key Findings:

• BREAST-Q scores improved from 42.38 ± 12.56 at baseline to 68.74 ± 14.23 at 12 months (p < 0.001).
• Pain scores decreased from 5.82 ± 2.14 to 1.45 ± 1.23 (p < 0.001).
• Quick-DASH scores improved from 38.67 ± 15.34 to 12.89 ± 8.76 (p < 0.001).
• SF-36 Physical Component Summary increased from 38.45 ± 8.92 to 48.76 ± 7.34 (p < 0.001).
• 89.4% achieved minimal clinically important differences for appearance satisfaction, 92.3% for pain, and 85.2% for function at 12 months.

Interpretation:

Surgical treatment for plasma cell mastitis results in significant and clinically meaningful improvements in breast function and quality of life sustained through 12 months.

Limitations:

• Retrospective design may introduce selection bias.
• Lack of a control group limits comparison with non-surgical management.

Conclusion:

The study supports the effectiveness of surgical intervention for improving patient-centered outcomes in women with plasma cell mastitis.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.